drugset / Trial / NCT06618664
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC (KYLIN-02).
Timeline
- Start
- 2024-10-28
- Primary completion
- 2026-10
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | SHR-8068 | Monoclonal antibody | 50 mg | Intravenous |
| Comparator | Sintilimab | Monoclonal antibody | 100 mg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 100 mg | Intravenous |